title: [Pravastatin increases the activity pf the LDL receptors in lymphocytes of individuals with heterozygous familial hypercholesterolemia].
abstract: An investigation was conducted on the effects of pravastatin, an inhibitor of the HMG CoA reductase, on lipoproteins concentrations and degradation of LDL (low density lipoproteins) in 14 patients with familial hypercholesterolemia (FH). Therapy with pravastatin for twelve weeks, 20 mg every 12 hours, and a low fat (30% calories) and cholesterol (less than 300 mg/daily) diet decreased serum concentrations of LDL cholesterol and apolipoprotein B by 35.5% and 24%, respectively (p < 0.001 for both parameters). On the other hand, apolipoprotein A-1 concentrations increased by 15.1% (p < 0.05) and HDL cholesterol (high density lipoproteins) by 6.8%; concentrations of apolipoprotein A-II did not change. LDL degradation in peripheral lymphocytes increased by 41.3% (p < 0.05) and a correlation was observed (p < 0.05) between percentage of LDL degradation and percentage in the LDL cholesterol decrease. Likewise, a positive trend (p = 0.057) was observed between increases in LDL degradation and aging. These findings indicate that pravastatin favorably influences the lipoprotein profile and that this effect is mediated, at least partly, by an increase in cellular capacity of LDL degradation.
authors.affiliation: Departamento de Medicina Interna, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid.
authors.forename: L A
authors.initials: LA
authors.lastname: Alvarez-Sala
authors.forename: P
authors.initials: P
authors.lastname: Mata
authors.forename: E
authors.initials: E
authors.lastname: Blázquez
authors.forename: J A
authors.initials: JA
authors.lastname: Garrido
authors.forename: J M
authors.initials: JM
authors.lastname: Ordovás
authors.forename: M J
authors.initials: MJ
authors.lastname: Rubio
authors.forename: M
authors.initials: M
authors.lastname: de Oya
mesh_terms: D000328:Adult; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001054:Apolipoproteins A / Q000378:metabolism; D001055:Apolipoproteins B / Q000378:metabolism; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D008077:Lipoproteins, LDL / Q000097:blood / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000627:therapeutic use*; D011973:Receptors, LDL / Q000187:drug effects* / Q000378:metabolism
chemical_list: D000924:Anticholesteremic Agents; D001054:Apolipoproteins A; D001055:Apolipoproteins B; D008077:Lipoproteins, LDL; D011973:Receptors, LDL; D017035:Pravastatin